Literature DB >> 11710996

Analysis of the antiviral activities of natural IFN-alpha preparations and their subtype compositions.

Y Yanai1, O Sanou, T Kayano, H Ariyasu, K Yamamoto, H Yamauchi, H Ikegami, M Kurimoto.   

Abstract

Here we report on the antiviral effects of two commercially available natural interferon-alpha (IFN-alpha) preparations, their subtype compositions, and the effects of combinations of pairs of the subtypes on virally infected cells. Our results show that the antiviral effects of these preparations depend on the target cell and on the infecting virus. The component subtypes vary with the preparations, and combinations of pairs of IFN-alpha subtypes may have synergistic or competitive effects. Our results suggest that optimal preparations of synergistically acting subtypes may provide more therapeutic benefit to patients.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11710996     DOI： 10.1089/107999001753238088

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN： 1079-9907            Impact factor:   2.607


  8 in total

1.  Rigid interferon-alpha subtype responses of human plasmacytoid dendritic cells.

Authors:  Richard Szubin; W L William Chang; Tamara Greasby; Laurel Beckett; Nicole Baumgarth
Journal:  J Interferon Cytokine Res       Date:  2008-12       Impact factor: 2.607

2.  High-throughput quantitative real-time polymerase chain reaction array for absolute and relative quantification of rhesus macaque types I, II, and III interferon and their subtypes.

Authors:  Lynnsie M Schramm; Kevin D Kirschman; Melissa Heuer; Aaron A Chen; Daniela Verthelyi; Montserrat Puig; Ronald L Rabin
Journal:  J Interferon Cytokine Res       Date:  2012-07-20       Impact factor: 2.607

3.  Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders.

Authors:  Toshio Ariyasu; Takeshi Tanaka; Noboru Fujioka; Yoshiaki Yanai; Shigeto Yamamoto; Hiroshi Yamauchi; Hakuo Ikegami; Masao Ikeda; Masashi Kurimoto
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 Jan-Feb       Impact factor: 2.416

4.  Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation.

Authors:  Catherine François; Isabelle Bernard; Sandrine Castelain; Bryan Charleston; Martin D Fray; Jean-Claude Capiod; Gilles Duverlie
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 5.  The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.

Authors:  Consuelo M López de Padilla; Timothy B Niewold
Journal:  Gene       Date:  2015-09-26       Impact factor: 3.688

6.  Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.

Authors:  Carolina Scagnolari; Milvia Casato; Francesca Bellomi; Francesca De Pisa; Ombretta Turriziani; Rossella Coviello; Maria Rosaria Pirro; Ferdinando Dianzani; Guido Antonelli
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

7.  Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent.

Authors:  Philippa Hillyer; Viraj P Mane; Lynnsie M Schramm; Montserrat Puig; Daniela Verthelyi; Aaron Chen; Zeng Zhao; Maria B Navarro; Kevin D Kirschman; Srikant Bykadi; Ronald G Jubin; Ronald L Rabin
Journal:  Immunol Cell Biol       Date:  2012-01-17       Impact factor: 5.126

Review 8.  Interferon-α Subtypes As an Adjunct Therapeutic Approach for Human Immunodeficiency Virus Functional Cure.

Authors:  Jeffy George; Joseph J Mattapallil
Journal:  Front Immunol       Date:  2018-02-22       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.